{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:53:28Z","timestamp":1771462408334,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1111\/bjd.16424","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T07:12:38Z","timestamp":1517814758000},"page":"50-53","source":"Crossref","is-referenced-by-count":6,"title":["Subcutaneous methotrexate in patients with moderate-to-severe psoriasis: a critical appraisal"],"prefix":"10.1093","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1895-6070","authenticated-orcid":false,"given":"T.","family":"Tsakok","sequence":"first","affiliation":[{"name":"St John's Institute of Dermatology; King's College London and Guy's and St Thomas\u2019 NHS Foundation Trust; Great Maze Pond London SE1 9RT U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4127-8263","authenticated-orcid":false,"given":"Z.K.","family":"Jabbar-Lopez","sequence":"additional","affiliation":[{"name":"St John's Institute of Dermatology; King's College London and Guy's and St Thomas\u2019 NHS Foundation Trust; Great Maze Pond London SE1 9RT U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-1144","authenticated-orcid":false,"given":"C.H.","family":"Smith","sequence":"additional","affiliation":[{"name":"St John's Institute of Dermatology; King's College London and Guy's and St Thomas\u2019 NHS Foundation Trust; Great Maze Pond London SE1 9RT U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"10.1111\/bjd.16424-BIB0001|bjd16424-cit-0001","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"key":"10.1111\/bjd.16424-BIB0002|bjd16424-cit-0002","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2230.2008.02976.x","article-title":"Methotrexate for psoriasis in the era of biological therapy","volume":"33","author":"Warren","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/bjd.16424-BIB0003|bjd16424-cit-0003","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1111\/bjd.16424-BIB0004|bjd16424-cit-0004","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000156599","article-title":"Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project","volume":"217","author":"Naldi","year":"2008","journal-title":"Dermatology"},{"key":"10.1111\/bjd.16424-BIB0005|bjd16424-cit-0005","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","article-title":"Obesity and psoriasis: body weight and body mass index influence the response to biological treatment","volume":"25","author":"Puig","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.16424-BIB0006|bjd16424-cit-0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/0974-1208.82352","article-title":"An overview of randomization techniques: an unbiased assessment of outcome in clinical research","volume":"4","author":"Suresh","year":"2011","journal-title":"J Hum Reprod Sci"},{"key":"10.1111\/bjd.16424-BIB0007|bjd16424-cit-0007","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jid.2017.04.009","article-title":"Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis","volume":"137","author":"Jabbar-Lopez","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16424-BIB0008|bjd16424-cit-0008","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/bjd.13908","article-title":"Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register","volume":"173","author":"Iskandar","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16424-BIB0009|bjd16424-cit-0009","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16424-BIB0010|bjd16424-cit-0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16424-BIB0011|bjd16424-cit-0011","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jclinepi.2015.03.007","article-title":"Unbalanced rather than balanced randomized controlled trials are more often positive in favor of the new treatment: an exposed and nonexposed study","volume":"68","author":"Dibao-Dina","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/bjd.16424-BIB0012|bjd16424-cit-0012","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjd.14816","article-title":"British Association of Dermatologists\u2019 guidelines for the safe and effective prescribing of methotrexate for skin disease 2016","volume":"175","author":"Warren","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16424-BIB0013|bjd16424-cit-0013","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16424-BIB0014|bjd16424-cit-0014","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","article-title":"A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis","volume":"365","author":"Reich","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16424-BIB0015|bjd16424-cit-0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.2011.10399.x","article-title":"Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study","volume":"165","author":"Saurat","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16424-BIB0016|bjd16424-cit-0016","doi-asserted-by":"crossref","first-page":"e0153740","DOI":"10.1371\/journal.pone.0153740","article-title":"Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials","volume":"11","author":"West","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1111\/bjd.16424-BIB0017|bjd16424-cit-0017","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16424-BIB0018|bjd16424-cit-0018","unstructured":"National Institute for Health and Care Excellence Methotrexate https:\/\/bnf.nice.org.uk\/drug\/methotrexate.html"},{"key":"10.1111\/bjd.16424-BIB0019|bjd16424-cit-0019","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.16424-BIB0020|bjd16424-cit-0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2133.2012.10881.x","article-title":"Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study","volume":"167","author":"Woolf","year":"2012","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16424\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:39:39Z","timestamp":1676381979000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/179\/1\/50\/6732316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16424","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5,9]]}}}